ZAI LAB (09688) released its interim financial results, with total revenue of 216 million US dollars, an increase of 15.35% year-on-year.

ZAI LAB (09688) announced its mid-year performance for 2025, with the group achieving total revenue of 216 million US dollars, a year-on-year increase of 15.35%; a net loss of 89.165 million US dollars, a year-on-year decrease of 33.33%; and a loss per share of 0.08 US dollars. Product revenue net increased by 27.5 million US dollars (or 15%) to 2.15 billion US dollars, mainly due to the sales of Wei Jia being driven by extended treatment courses and increased market penetration, the sales of Niu Zailu being driven by improved market coverage and penetration, and the sales growth of Ding Youle, which has been listed since the fourth quarter of 2024. Research and development expenses decreased by 4.9 million US dollars (or 4%) to 1.11 billion US dollars, mainly due to ongoing resource optimization and efficiency improvements leading to reduced personnel and clinical trial costs, partially offset by an increase in licensing fees.